Table 2.
Side effects of neoadjuvant therapy in the matched cohort
| Toxicity | Matched NAC (n=413) | Full NAC cohort (n=694) |
|---|---|---|
| AE N (%) | ||
| Yes | 378(91.53) 35(8.47) |
645(92.94) |
| No | 35(8.47) | 49(7.06) |
| CTCAE grade N (%) | ||
| missing | 35 | 49 |
| I | 87(23.02) | 140(21.71) |
| II | 184(48.68) | 329(51.01) |
| III | 81(21.43) | 135(20.93) |
| IV | 26(6.88) | 41(6.36) |
| Leukopenia | ||
| 0 | 221 | 319 |
| I | 94(48.96) | 166(52.04) |
| II | 61(31.77) | 96(30.09) |
| III | 27(14.06) | 42(13.17) |
| IV | 10(5.21) | 15(4.70) |
| Anaemia | ||
| 0 | 135 | 208 |
| I | 199(71.58) | 344(70.78) |
| II | 74(26.62) | 133(27.37) |
| III | 5(1.80) | 9(1.85) |
| IV | 0(0.00) | 0(0.00) |
| Thrombocytopenia | ||
| 0 | 80 | 550 |
| I | 53(66.25) | 101(70.14) |
| II | 22(27.50) | 37(25.69) |
| III | 4(5.00) | 5(3.47) |
| IV | 1(1.25) | 1(0.69) |
| Neutropenia | ||
| 0 | 265 | 440 |
| I | 52(35.14) | 94(37.01) |
| II | 49(33.11) | 82(32.28) |
| III | 26(17.57) | 42(16.54) |
| IV | 21(14.19) | 36(14.17) |
| Total bilirubin increased | ||
| 0 | 125 | 486 |
| I | 95(76.00) | 153(73.56) |
| II | 29(23.20) | 53(25.48) |
| III | 1(0.80) | 2(0.96) |
| IV | 0(0.00) | 0(0.00) |
| Creatinine | ||
| 0 | 395 | 661 |
| I | 17(94.44) | 30(90.91) |
| II | 1(5.56) | 2(6.06) |
| III | 0(0.00) | 1(3.03) |
| IV | 0(0.00) | 0(0.00) |
| Emesis | ||
| Yes | 23(5.57) | 51(7.35) |
| No | 390(94.43) | 643(92.65) |
| Diarrhoea | ||
| Yes | 2(0.48) | 2(0.29) |
| No | 411(99.52) | 692(99.71) |
NAC, neoadjuvant chemotherapy; N, number; AE, adverse effect; CTCAE, Common Terminology Criteria for Adverse Events.